Changeflow GovPing Healthcare & Life Sciences Novel Antibiotic Nidaromycin from New Gene Cluster
Routine Notice Added Draft

Novel Antibiotic Nidaromycin from New Gene Cluster

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260109688A1 on April 23, 2026, covering a novel antibiotic compound termed nidaromycin and its associated biosynthetic gene cluster (BGC). The application also discloses related genes, nucleic acid molecules, constructs, vectors, and host cells for producing nidaromycin, as well as methods of use. As a patent application, no enforceable rights exist yet; the invention remains subject to examination before any patent grant.

“The present invention provides a new antibiotic compound termed nidaromycin derived from a new biosynthetic gene cluster (BGC), and its uses.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

USPTO classification C07D covers heterocyclic organic compounds: the chemical core of most small-molecule drugs, including kinase inhibitors, GLP-1 receptor agonists, antibiotics, antivirals, and CNS therapies. Every newly published application in C07D lands in this feed, around 160 a month. Applications publish 18 months after filing, so this feed reveals what medicinal chemistry groups at Pfizer, Novartis, Roche, Shionogi, and others were synthesizing in the prior year and a half. Watch this if you run a medicinal chemistry program, file patent clearance for new drug candidates, scout competitor pipelines before clinical readouts, or track heterocyclic innovation across therapeutic areas.

What changed

The USPTO published patent application US20260109688A1 disclosing nidaromycin, a new antibiotic compound derived from a previously unknown biosynthetic gene cluster. The application covers the compound itself, associated genes and nucleic acid molecules encoding the biosynthetic machinery, and constructs, vectors, and host cells for expressing the BGC. CPC classifications indicate applications in C07D (heterocyclic compounds), A61K31/7036 (medicinal preparations containing antibiotics), and A61P31/04 (anti-infectives).

Affected parties include pharmaceutical companies engaged in antibiotic research and development, as well as entities pursuing novel antimicrobial therapeutics derived from biosynthetic gene clusters. While the application creates no immediate compliance obligations, it signals prior art that could affect freedom-to-operate analyses for competing antibiotic development programs. Parties with overlapping R&D activities should review the published claims once available.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

NOVEL ANTIBIOTIC COMPOUND

Application US20260109688A1 Kind: A1 Apr 23, 2026

Inventors

Alexander WENTZEL, Kristin Fløgstad DEGNES, Giang-Son NGUYEN, Geir KLINKENBERG, Håvard SLETTA, Trond Erling ELLINGSEN, Mario Dino VAN DISSEL, Gilles VAN WEZEL, Marnix MEDEMA, Antonio FERNANDEZ-GUERRA

Abstract

The present invention provides a new antibiotic compound termed nidaromycin derived from a new biosynthetic gene cluster (BGC), and its uses. Also provided herein are novel genes and nucleic acid molecules encoding the biosynthetic machinery for the production of nidaromycin, and to constructs, vectors, and host cells for expressing the BGC and methods for producing the compound.

CPC Classifications

C07D 405/14 A61K 31/7036 A61P 31/04 C12N 1/20 C12N 15/76 C12R 2001/465

Filing Date

2023-05-16

Application No.

18864850

View original document →

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260109688A1

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Drug discovery Antibiotic research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!